Literature DB >> 2857124

Endocytosis of an antibody ricin A-chain conjugate (immuno-A-toxin) adsorbed on colloidal gold. Effects of ammonium chloride and monensin.

D Carrière, P Casellas, G Richer, P Gros, F K Jansen.   

Abstract

An immunotoxin (IT) formed by a specific antibody coupled to the ricin A chain was adsorbed on colloidal gold particles (IT-Au). Binding and internalization of IT-Au in human lymphoblastic CEM cells were studied using electron microscopy. IT-Au showed specific cytotoxic activity toward the target cells. After 1 h at 4 degrees C, IT-Au were linked diffusely to the plasma membrane with 45% of the particles regrouped in clusters. Upon transfer to 37 degrees C, the particles carrying the ligand were regrouped more frequently and internalized into the cell by endocytosis through smooth microinvaginations or coated pits of the plasma membrane. After 15 min, IT-Au was observed in endocytic vacuoles, or receptosomes, in tubular structure near the Golgi apparatus and in lysosomes. Entry of IT-Au into lysosomes was rapid (around 50% of intracellular IT-Au particles after 30 min). NH4Cl or monensin, well-known potentiators of immunotoxin activity, when present in incubation medium, altered neither the processes nor the rate of IT-Au endocytosis. In the presence of either of these substances, IT-Au accumulated in the normal or often enlarged endocytic vacuoles, and entry into the lysosomes was slowed down (50% of particles after 2 h 15 min). We conclude that this intense slowing-down in the speed of IT-Au transportation into lysosomes and the functional modifications of these organelles help to explain the increased efficacy of immunotoxins in the presence of potentiators.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2857124

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  10 in total

Review 1.  Immunotoxins against solid tumors.

Authors:  R Pirker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

2.  Routing of internalized ricin and ricin conjugates to the Golgi complex.

Authors:  B van Deurs; T I Tønnessen; O W Petersen; K Sandvig; S Olsnes
Journal:  J Cell Biol       Date:  1986-01       Impact factor: 10.539

3.  Immunocytochemical detection of ricin. II. Further studies using the immunoperoxidase method.

Authors:  G D Griffiths; H V Newman; D J Gee
Journal:  Histochem J       Date:  1986-04

4.  Potentiation of a weakly active ricin A chain immunotoxin recognizing the neural cell adhesion molecule.

Authors:  E J Derbyshire; R A Stahel; E J Wawrzynczak
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

5.  Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity.

Authors:  G R Braslawsky; K Kadow; J Knipe; K McGoff; M Edson; T Kaneko; R S Greenfield
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  The effect of ricin B chain on the intracellular trafficking of an A chain immunotoxin.

Authors:  J Timar; D P McIntosh; R Henry; A J Cumber; G D Parnell; A J Davies
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

7.  Potent cytotoxic action of the immunotoxin SWA11-ricin A chain against human small cell lung cancer cell lines.

Authors:  E J Derbyshire; R V Henry; R A Stahel; E J Wawrzynczak
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

Review 8.  Drug-targeting by monoclonal antibodies.

Authors:  M J Embleton
Journal:  Br J Cancer       Date:  1987-03       Impact factor: 7.640

9.  Internalization of a monoclonal antibody against human breast cancer by immunoelectron microscopy.

Authors:  G Della Torre; S Canevari; R Orlandi; M I Colnaghi
Journal:  Br J Cancer       Date:  1987-04       Impact factor: 7.640

10.  Factors governing the competition between group IA and IB cations for monensin A: a DFT/PCM study.

Authors:  Todor Dudev; Diana Cheshmedzhieva; Radoslava Dimitrova; Peter Dorkov; Ivayla Pantcheva
Journal:  RSC Adv       Date:  2020-02-04       Impact factor: 3.361

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.